Yahoo Finance • 18 days ago
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) released topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS). Fragile X syndrome is a rare genetic disorder that is th... Full story
Yahoo Finance • 18 days ago
Shares of Harmony Biosciences plunged Wednesday as Fragile X syndrome continued to be "undruggable" for the biotech company. Continue Reading View Comments... Full story
Yahoo Finance • 23 days ago
Investors in Harmony Biosciences Holdings Inc (Symbol: HRMY) saw new options become available this week, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HRMY options chain for... Full story
Yahoo Finance • last month
The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields. HARMONY BIOSCIENCES H... Full story
Yahoo Finance • last month
Investors looking for growth chances often meet the difficulty of balancing expansion possibility with fair prices, a method usually called Growth at a Reasonable Price (GARP). This method looks for companies showing solid growth paths, go... Full story
Yahoo Finance • 2 months ago
Harmony Biosciences Holdings (NASDAQ:HRMY [https://www.chartmill.com/stock/quote/HRMY]) has been identified through a systematic screening process designed to find stocks with good fundamental characteristics at appealing valuations. This... Full story
Yahoo Finance • 2 months ago
Investors looking for growth opportunities without paying too much often use the "Affordable Growth" strategy, which focuses on companies with strong growth potential and reasonable prices. This method combines the appeal of high-growth st... Full story
Yahoo Finance • 2 months ago
Harmony Biosciences Holdings (NASDAQ:HRMY [https://www.chartmill.com/stock/quote/HRMY]) has become an interesting option for investors looking for growth stocks with positive technical setups. The selection method blends fundamental and te... Full story
Yahoo Finance • 2 months ago
The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields. GRIFFON CORP (GFF) is... Full story
Yahoo Finance • 2 months ago
Harmony Biosciences Holdings (HRMY) reported its second-quarter 2025 earnings, showcasing a stronger-than-expected earnings per share (EPS) of $0.92, surpassing the forecast of $0.72 by 27.78%. The company’s revenue, however, fell slightly... Full story
Yahoo Finance • 2 months ago
Investing.com - Harmony Bio (NASDAQ: HRMY) reported second quarter EPS of $0.92, $0.20 better than the analyst estimate of $0.72. Revenue for the quarter came in at $200.5M versus the consensus estimate of $204.59M. Guidance Harmony Bio... Full story
Yahoo Finance • 3 months ago
Harmony Biosciences Holdings (NASDAQ:HRMY [https://www.chartmill.com/stock/quote/HRMY]) has been recognized through a "Decent Value" screening method, focusing on stocks with solid fundamental valuation metrics, good profitability, financi... Full story
Yahoo Finance • 3 months ago
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Mixed analysts’ sentiments for the stock, following the presentation of preclinical data for BP1.15205.Harmony Biosciences Advances... Full story
Yahoo Finance • 3 months ago
Investing.com - H.C. Wainwright has reiterated its Buy rating and $70.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ:HRMY), currently trading at $35.20, following a management meeting on July 17. According to InvestingPro... Full story
Yahoo Finance • 3 months ago
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 7 most undervalued pot stocks to buy according to analysts. On June 23, Mizuho reiterated its “Outperform” rating on Harmony and maintained a price target of $48. The reaffirma... Full story
Yahoo Finance • 3 months ago
Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) is one of the most undervalued small-cap stocks to buy according to analysts. On June 11, Harmony Biosciences Holdings presented promising preclinical pharmacological data for BP1.15205, whic... Full story
Yahoo Finance • 3 months ago
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 30, H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Harmony Biosciences Holdings, Inc. (NASDA... Full story
Yahoo Finance • 3 months ago
In trading on Tuesday, shares of Harmony Biosciences Holdings Inc (Symbol: HRMY) crossed above their 200 day moving average of $31.31, changing hands as high as $34.40 per share. Harmony Biosciences Holdings Inc shares are currently tradi... Full story
Yahoo Finance • 4 months ago
Investing.com - Mizuho maintained its Outperform rating and $48.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ:HRMY), representing significant upside from the current price of $31.89, following the company’s presentation o... Full story
Yahoo Finance • 4 months ago
We came across a bullish thesis on Harmony Biosciences Holdings, Inc. (HRMY) on Capital Curiosity’s Substack by Taylor Nichols. In this article, we will summarize the bulls’ thesis on HRMY. Harmony Biosciences Holdings, Inc. (HRMY)'s share... Full story